1. 210TiPIMbrave150: A randomised phase III study of atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma. (25th November 2018) Authors: Qin, S; Cheng, A-L; Ducreux, M P; Galle, P R; Zhu, A; Kim, T-Y; Xu, D-Z; Verret, W; Liu, J; Finn, R S; Ikeda, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 59PDFinal analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]. (23rd October 2018) Authors: Finn, R S; Kudo, M; Cheng, A-L; Wyrwicz, L; Ngan, R; Blanc, J F; Baron, A D; Vogel, A; Ikeda, M; Piscaglia, F; Han, K-H; Qin, S; Minoshima, Y; Kanekiyo, M; Ren, M; Dairiki, R; Tamai, T; Dutcus, C E; Funahashi, Y; Evans, T R J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 622PDRamucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH). (23rd October 2018) Authors: Zhu, A X; Finn, R S; Galle, P R; Llovet, J M; Blanc, J F; Okusaka, T; Chau, I; Cella, D; Girvan, A; Gable, J; Bowman, L; Hsu, Y; Abada, P B; Kudo, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 776TiPGlobal phase III study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress. (23rd October 2018) Authors: Qin, S; Finn, R S; Kudo, M; Meyer, T; Vogel, A; Ducreux, M P; Macarulla, T M; Tomasello, G; Boisserie, F; Hou, J; Li, C; Song, J; Zhu, A X Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Iloprost-induced rash. Issue 10 (28th September 2009) Authors: Finn, R S; Beckert, L; Troughton, R Journal: Thorax Issue: Volume 64:Issue 10(2009) Page Start: 917 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. (19th January 2018) Authors: Rugo, H S; Diéras, V; Gelmon, K A; Finn, R S; Slamon, D J; Martin, M; Neven, P; Shparyk, Y; Mori, A; Lu, D R; Bhattacharyya, H; Bartlett, C Huang; Iyer, S; Johnston, S; Ettl, J; Harbeck, N Journal: Annals of oncology Issue: Volume 29:Number 4(2018) Page Start: 888 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. O-027Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240. (2nd July 2019) Authors: Finn, R S; Ryoo, B-Y; Merle, P; Kudo, M; Bouattour, M; Lim, H-Y; Breder, V; Edeline, J; Chao, Y; Ogasawara, S; Yau, T; Garrido, M; Chan, S L; Knox, J; Daniele, B; Ebbinghaus, S W; Chen, E; Siegel, A B; Zhu, A X; Cheng, A-L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P65 Is serum N-terminal pro B type natriuretic peptide (NT-proBNP) measurement useful in the investigation of unilateral pleural effusions?—a prospective observational study. (16th November 2010) Authors: Hooper, C E; Rider, I; Finn, R S; Morley, A J; Harvey, J E; Skyrme-Jones, A; Maskell, N A Journal: Thorax Issue: Volume 65(2010)Supplement 4 Page Start: A105 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗